Personalis surges 8.7% on strong Q4 beat, Medicare coverage boost
Cancer genomics company raises 2026 guidance on 5x clinical revenue growth with new reimbursement for breast and lung cancer tests
Personalis shares jumped 8.7% in Thursday trading after the cancer genomics company reported fourth-quarter results that handily beat analyst expectations and raised full-year 2026 guidance, bolstered by recent Medicare coverage decisions for its flagship cancer surveillance test.
The Menlo Park-based company reported revenue of $17.3 million for the fourth quarter of 2025, exceeding the consensus estimate of $13.3 million by 30.3%. The loss per share of $0.26 improved on the expected loss of $0.274, representing a 5.2% beat on the bottom line. The strong quarterly performance helped offset a broader annual decline, with full-year 2025 revenue falling 18% year-over-year to $69.6 million from $84.6 million in 2024.
The stock's rally, which pushed shares to $9.03, was primarily driven by management's forward-looking guidance rather than historical results. Personalis projected 2026 revenue of $78 million to $80 million, representing growth of 12% to 15% from 2025 levels. More significantly, the company indicated clinical revenue would surge approximately five-fold to $10-11 million, driven by approximately 43,000 to 45,000 tests anticipated for the year.
That revenue outlook rests on pivotal reimbursement decisions that have transformed Personalis's commercial prospects. In February 2026, the company secured Medicare coverage for its NeXT Personal cancer recurrence test for surveillance in Stage I to III non-small cell lung cancer patients, expanding upon November 2025 coverage for Stage II and III breast cancer patients across all major subtypes. The breast cancer coverage, which became effective October 7, 2025, applies for recurrence monitoring for up to six years following treatment.
The NeXT Personal test is a tumor-informed molecular residual disease liquid biopsy designed to detect circulating tumor DNA, often before standard imaging techniques can identify recurring tumors. This ultrasensitive detection capability aims to provide earlier insights that can shape cancer treatment decisions and potentially improve patient outcomes.
"These Medicare coverage decisions significantly expand patient access to NeXT Personal for two of the most common cancers in the United States," the company stated, noting that the coverage decisions were supported by clinical evidence including data from the landmark TRACERx collaboration for lung cancer and studies demonstrating earlier detection of breast cancer recurrence compared to standard imaging.
Investors appear to be focusing on the company's substantial cash position and improved commercial prospects rather than ongoing operational losses. Personalis ended 2025 with approximately $240 million in cash, cash equivalents, and short-term investments, providing a substantial runway as it scales clinical operations. The company reported a full-year net loss of $81.3 million in 2025.
Analysts remain broadly optimistic on the stock, with six analysts rating Personalis a buy or strong buy and one maintaining a hold rating, according to market data. The consensus price target of $11.29 implies approximately 25% upside from current levels, though the stock has already recovered significantly from its 52-week low of $2.83 reached last year. The shares are still trading below their 52-week high of $11.50.
The institutional confidence is evident in the ownership structure, with 75.2% of shares held by institutional investors. Insiders maintain a 31.7% stake, suggesting management alignment with shareholder interests despite the stock's high-beta profile of 2.02, indicating significant volatility relative to the broader market.
The 2026 guidance assumes the 5x growth in clinical revenue will drive the company's overall expansion, though questions remain about the pace at which Medicare beneficiaries and their oncology providers will adopt the new surveillance protocol. The company's ability to convert the reimbursement decisions into sustained test volume will be the key metric to watch in the coming quarters.
Personalis, which went public in 2021, has been transitioning from primarily serving pharmaceutical companies with its advanced genomic sequencing services to building a direct-to-patient clinical testing business. The Medicare coverage decisions represent a critical validation of this strategic pivot and provide a clearer path to commercial scale.
The strong market reaction Thursday reflects investor enthusiasm for what could be a turning point for the precision diagnostics company. With $240 million in cash and newly secured reimbursement for two major cancer indications, Personalis has both the financial resources and commercial runway to execute its growth strategy in 2026.